Glioblastoma Market | Size, Share, Growth

Glioblastoma Market | Size, Share, Growth | 2022 - 2032

Published: 2025 - January

Report Code: VMR-12758

Region: Global

Request Sample

Customization

Ask an Expert

Enquire Enquire Before Buying

The Glioblastoma market focuses on the treatment and management of glioblastoma multiforme (GBM), a highly aggressive and malignant form of brain cancer. Glioblastoma is characterized by rapid growth and the presence of necrotic areas in the tumor. The market includes various treatment options such as chemotherapy, radiotherapy, immunotherapy, and targeted therapies, with a growing emphasis on personalized and novel therapies to improve patient outcomes.

Disruptive Impact and Opportunities:

The Glioblastoma market is witnessing disruptive shifts driven by the development of targeted therapies and immunotherapies. Innovations like gene therapies, immune checkpoint inhibitors, and personalized treatment approaches offer the potential for improved patient survival rates and quality of life. These advances also present opportunities to address unmet needs in treatment efficacy, given the high recurrence rates and poor prognosis associated with GBM.
The market is ripe for solutions that are new (novel treatments), easy (patient-friendly administration), safe (minimizing side effects), and big (addressing a global population with significant unmet needs).

Emerging Drugs:

Onfekafuspalfa
PLX3397
APVAC1

INO5401

Olaptesed pegol

Marketed Drugs:

TVB2640

Trabedersen

Key Companies:

Array Biopharma
AstraZeneca
Double Bond Pharmaceuticals
Philogen
Immatics N.V
BioNTech
InovioPharma

Noxxon Pharma

Celgene Corporation

Market Segmentation:

By Type

Primary Glioblastoma
Secondary Glioblastoma

By Administration Type

Oral Administration

Intravenous (IV) Administration
Intratumoral Administration

What’s in It for You?

Gain insights into key players and their strategic moves in glioblastoma treatment.
Identify promising emerging therapies and market segments with high growth potential.
Understand the evolving landscape of glioblastoma treatment, including the shift toward immunotherapy and personalized approaches.
Navigate through the regulatory environment and approval trends for new glioblastoma therapies.

Build long-term growth strategies by leveraging insights on emerging drugs and technologies in glioblastoma treatment.

Glioblastoma Market Analysis (Market Size & CAGR, Epidemiology, Marketed Therapies, Emerging Drugs, Clinical Trials, Key Approvals & Anticipated Loss of Exclusivity, Opportunities, Unmet Needs, Company Profiles)

1. Glioblastoma Market - Executive Summary

1.1. Introduction

1.2. Objectives

1.3. Key Findings

1.3.1. Market Size 2025 & 2030: By Key Country (10MM)

1.3.2. Global Market Size 2025 & 2030: By Key Segment

1.3.3. Key Investments & Startup Analysis

1.4. Research Methodology

2. Understanding the Disease

2.1. Disease Overview

2.2. Classification

2.3. Signs and Symptoms

2.4. Risk Factors

2.5. Causes

2.6. Disease Biology & Digital Innovations

2.7. Stages & Staging System

2.8. Diagnostic Algorithm

2.9. Current Treatment Practices & Algorithm

2.10. Current Standard of Care and Treatment Gaps

2.11. Patient Demographics and Treatment Pathways

3. Guidelines

4. Unmet Needs

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 10MM

5.3. Epidemiology Scenario: 10MM

5.4. U.S. Epidemiology Scenario

5.5. EU-5 Epidemiology

5.5.1. U.K. Epidemiology Scenario

5.5.2. Germany Epidemiology Scenario

5.5.3. France Epidemiology Scenario

5.5.4. Italy Epidemiology Scenario

5.5.5. Spain Epidemiology Scenario

5.6. Japan Epidemiology Scenario

5.7. China Epidemiology Scenario

5.8. Australia Epidemiology Scenario

5.9. India Epidemiology Scenario

6. Real-world Data & Real-world Evidence

7. Drug Development Landscape

7.1. Existing Key Drug Candidate Profiles/ Marketed Therapies

7.1.1. Trabedersen

7.1.1.1. Product Description

7.1.1.2. Regulatory Milestones

7.1.1.3. Other Developmental Activities

7.1.1.4. Pivotal Clinical Trials

7.1.1.5. Ongoing Current Pipeline Activity

7.1.2. TVB2640

7.1.2.1. Product Description

7.1.2.2. Regulatory Milestones

7.1.2.3. Other Developmental Activities

7.1.2.4. Pivotal Clinical Trials

7.1.2.5. Ongoing Current Pipeline Activity

7.2. Competitive Analysis and Differentiation

7.3. Overview of Similar/Competing Drugs in Clinical Trials

7.4. Future Trends and Emerging Drugs

7.4.1. PLX3397

7.4.1.1. Product Description

7.4.1.2. Clinical Development

7.4.1.3. Safety and Efficacy

7.4.2. APVAC1

7.4.2.1. Product Description

7.4.2.2. Clinical Development

7.4.2.3. Safety and Efficacy

7.4.3. INO5401

7.4.3.1. Product Description

7.4.3.2. Clinical Development

7.4.3.3. Safety and Efficacy

7.4.4. L19TNF

7.4.4.1. Product Description

7.4.4.2. Clinical Development

7.4.4.3. Safety and Efficacy

8. Regulatory Strategy and Potential Challenges

8.1. Regulatory Pathways in Key Markets

8.2. Anticipated Regulatory Hurdles and Mitigation Strategies

8.3. Case Studies in Oncology Drug Regulation

8.4. Impact of Potential Changes to Regulatory Framework

9. Commercial Landscape

9.1. Market Size & Growth Rates

9.2. Key Approvals & Anticipated Loss of Exclusivity

9.3. PESTLE & Porter’s Five Forces Analysis

9.4. Market Shares, Positioning/Ranking

9.5. Market Drivers

9.6. Identification of Threats

9.7. Digital Evolution in Commercialization

10. Market Segmentation

10.1. Market by Therapy Type

10.1.1. Surgery

10.1.2. Radiation Therapy

10.1.3. Chemotherapy

10.1.4. Targeted Therapy

10.1.5. Immunotherapy

10.1.6. Others

10.2. Market by Type

10.2.1. Primary Glioblastoma

10.2.2. Secondary Glioblastoma

11. Pricing, Reimbursement, and Access

11.1. Competitive Pricing Analysis

11.2. Reimbursement Landscape and Challenges

11.3. Strategies for Market Access and Equity

11.4. Patient Spending/Expenditure Analysis

12. Future Trends, Disruptions, and Opportunities

12.1. Analysis of Emerging Trends

12.2. Technological Impact

12.3. Impact of Potential Market Disruptors

12.4. Opportunities for Future Development and Expansion

12.5. Considerations for Investment Opportunities

13. Global Market Dynamics

13.1. Regional Regulatory Disparities

13.2. Cross-Border Partnership Strategies

13.3. Global Supply Chain Dynamics

13.4. Case Studies: Success and Failure in Global Markets

13.5. Strategies for Global Expansion and Localization

14. Company Profiles

14.1. Array Biopharma

14.2. AstraZeneca

14.3. Immatics N.V

14.4. Novartis

14.5. Merck

14.6. Pfizer

14.7. Roche

14.8. Oncotelic Therapeutics

14.9. Autotelic Therapeutics

14.10. Yumanity Therapeutics

Download Sample

Full Name *

Job Title *

Company *

Email *

Phone *

Country *

Message

↻

The field with (*) is required.

Choose License Type

Excel Data Pack

2500

Single User

4250

Multi User

5250

Corporate User

6900